Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.


Journal

Hematology (Amsterdam, Netherlands)
ISSN: 1607-8454
Titre abrégé: Hematology
Pays: England
ID NLM: 9708388

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 30 4 2024
pubmed: 30 4 2024
entrez: 30 4 2024
Statut: ppublish

Résumé

This study aims to investigate the correlation between NK and NKT cell proportion disparities and prognosis in patients with acute myeloid leukemia (AML). Forty-four cases of acute myeloid leukemia patients were selected, and flow cytometry was utilized to evaluate the expression of bone marrow NK and NKT cells. Next-generation sequencing technology was employed to detect genetic mutations in these 44 AML patients, and the rates of first induction remission and overall survival were recorded. Comparisons were made to analyze the respective differences in NK and NKT cell proportions among AML patients with various genetic mutations and risk stratifications. The FLT-3-ITD+ group exhibited a significant increase in the proportion of NK cells compared to the normal control group and FLT3-ITD+/NPM1+ group, whereas the proportion of NKT cells was significantly decreased. Additionally, the CEBPA+ group showed an increased proportion of NKT cells compared to the TP53+ group and ASXL1+ group. The high-risk group had a higher proportion of NK cells than the intermediate-risk group, while the proportion of NKT cells was lower in the high-risk group compared to the intermediate-risk group.Patients achieving first induction remission displayed a higher proportion of NKT cells at initial diagnosis compared to those who did not achieve remission. The distribution of NK cells show significant differences among AML patients in different survival periods. This results implies that distinct genetic mutations may play a role not only in tumor initiation but also in shaping the tumor microenvironment, consequently impacting prognosis.

Sections du résumé

BACKGROUND UNASSIGNED
This study aims to investigate the correlation between NK and NKT cell proportion disparities and prognosis in patients with acute myeloid leukemia (AML).
METHODS UNASSIGNED
Forty-four cases of acute myeloid leukemia patients were selected, and flow cytometry was utilized to evaluate the expression of bone marrow NK and NKT cells. Next-generation sequencing technology was employed to detect genetic mutations in these 44 AML patients, and the rates of first induction remission and overall survival were recorded. Comparisons were made to analyze the respective differences in NK and NKT cell proportions among AML patients with various genetic mutations and risk stratifications.
RESULTS UNASSIGNED
The FLT-3-ITD+ group exhibited a significant increase in the proportion of NK cells compared to the normal control group and FLT3-ITD+/NPM1+ group, whereas the proportion of NKT cells was significantly decreased. Additionally, the CEBPA+ group showed an increased proportion of NKT cells compared to the TP53+ group and ASXL1+ group. The high-risk group had a higher proportion of NK cells than the intermediate-risk group, while the proportion of NKT cells was lower in the high-risk group compared to the intermediate-risk group.Patients achieving first induction remission displayed a higher proportion of NKT cells at initial diagnosis compared to those who did not achieve remission. The distribution of NK cells show significant differences among AML patients in different survival periods.
CONCLUSION UNASSIGNED
This results implies that distinct genetic mutations may play a role not only in tumor initiation but also in shaping the tumor microenvironment, consequently impacting prognosis.

Identifiants

pubmed: 38687637
doi: 10.1080/16078454.2024.2346965
doi:

Substances chimiques

Nucleophosmin 117896-08-9
NPM1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2346965

Auteurs

ZhongLi Hu (Z)

Department of Haematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, People's Republic of China.
Anhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical University, Bengbu, People's Republic of China.

YanLi Yang (Y)

Department of Haematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, People's Republic of China.

JiaJia Li (J)

Department of Haematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, People's Republic of China.

ZhongTing Hu (Z)

Office of Academic Research, Bengbu Medical University, Bengbu, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH